Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
'Anavex releases positive data from Scout program, has Orphan Drug Designation and has now granted funding for a clinical trial'
OK...maybe you should watch this again:
https://www.reddit.com/r/videos/comments/5icnbh/tv_news_show_in_australia_shows_unprecedented/
How many times have you seen a biotech stop AD in its tracks and reverse symptoms?
Nuff said.
How many shares this time?
'Patience is a virtue', a wise poet once wrote.
I think you know the answer to your own question.
I believe so.
Patent can be extended for any new IND treated with A2-73.
Merck CEO: Alzheimer's Tsunami Coming
http://www.foxbusiness.com/features/2017/01/10/merck-ceo-alzheimers-tsunami-coming.html
Moneyshow Top Picks 2017: Anavex Life Sciences
http://www.moneyshow.com/articles/tptp072513-45524/top-picks-2017--anavex-life-sciences/
If you dive into who is really pulling the strings behind Big Pharma and the mainstream media, you will find striking similarities. I'll give you one name to start with; Rotschild.
Right. It even looks like they are under the assumption that the 5 week results came out during Phase I. And then they blame Anavex for the created hype and that they should be held accountable. And ofcourse, no mention of 57 week results. Oh well, once a fool always a fool I guess.
Healthcare podcast with Motley Fool's Todd Campbell discussing Anavex (around 16 minutes mark).
http://www.nasdaq.com/article/top-biotech-resolutions-for-2017-cm731145
Where did I say he looks out for the little guy? I can only hope he looks out for his business and the millions of Alzheimers sufferers he tries to help. What's good for him, may be good for us long investors.
We have someone at the helm who is a Kellogg Management School graduate, where his focus was on business partnerships. He is no fool when it comes to negotiations, be it buy-out or partnerships with other pharmas.
That testimony with a practically CURED Ern Heaven and his happy wife saying she has her husband back and that many others in the trial are doing great as well doesn't really help to temper my optimism. What to do now?
Dr. Missling also made it his personal mission as he lost his grandparents to Alzheimer's.
Merry Christmas to all.
Mr. Ern Heaven is living proof of that.
OK while you guys are being 'cautiously optimistic', the rest of us are loading up in the high 3's/low 4's (if you don't mind).
And for anyone having doubts about Missling's 2016 compensation, here's the explanation from IR:
Nice to see some coverage in Chinese language.
http://www.epochtimes.com/b5/16/12/16/n8598063.htm
Google translate:
Alzheimer's drug trials are expected to make breakthroughs since the 1990s, according to a report by the Journal of the American News Agency. Melbourne last year to become the world's first trial to research ANAVEX 2-73 in the city, initial test results are exciting. Next year, Australia will have nearly 300 people involved in the drug's clinical trials.
According to the Sun Herald, the results of the ANAVEX 2-73 early-stage clinical trial show that Anavex not only suppresses the deterioration of dementia symptoms, but also reverses the effects of dementia and the recovery of some body functions. The drug is currently in Phase II-III clinical trials.
The report shows that 32 patients from the Melbourne Caulfield Hospital, Austin Hospital, Royal Melbourne Hospital and St Vincent's Hospital were involved in the early clinical trials of the drug and have been able to recover some of their previous incapacities, such as jokes, dialogue, reading , play the piano, read the movie storyline, paint, play golf, travel, and remembering memories that had been forgotten.
Although the drug is hopeful to become a therapeutic drug, pending the validation of efficacy reports in subsequent trials, Steve Macfarlane, an associate professor at Monash University, has been stunned by its early results.
Macfarlane said: "The results of the current phase of the test is unprecedented, I have never seen in early clinical response, which means that the patient's condition more than 12 months ago to reduce the number of early test results ultimately depends on the credibility Whether it can be confirmed in a wider range of trials, which are scheduled for next year. "
In current treatment modalities, patients with moderate Alzheimer's disease typically lose about 2 points a year in cognitive tests out of 30. However, patients who participated in the Anavex clinical trial experienced an average of 1.8 points in cognitive tests, and some patients with a high degree of positive response to the drug regained more capacity and body function.
Because Anavex drugs help the patient's immune system fight nervous system diseases by regulating homeostasis, Christopher Missling, CEO of Anavex Life Sciences, hopes that the drug will also be effective against other neurological diseases, including Parkinson's disease and Multiple sclerosis to bring efficacy.
Biogen, the biotechnology company, has also made encouraging progress this month in developing Aducanumab, a dementia drug. Its early results show that the drug reduces the increase in amyloid plaques in the brains of Alzheimer's patients.
Anavex Early Response:
Can make fun
Like talking, more willing to communicate with people
Hand coordination improved
Able to read
Playing piano and spectrum recovery ability
Be able to understand the film story
Start painting again
Can write to his family
Able to travel and talk about travel experience
Cognitive ability, mood more stable
Editor: Li Xinran
As Einstein said long ago: Two things are infinite: the Universe and human stupidity; and I’m not sure about the Universe.
All these so called 'Alzheimer's groups' leave their followers in the dark. The only thing they will report on are ineffective treatments like stroboscope-, soundwaves- and other amyloid removal therapies. And while they are at it, asking for your donation ofcourse.
Here's an interesting read concerning patent issue from Pfizer:
http://www.patentdocs.org/2014/12/the-uncomfortable-intersection-between-the-practice-of-medicine-and-reality.html
Received a newsletter from BI Research yesterday and thought I would share here so to give you a sense of the enthusiasm out there.
Is anyone able to watch this video?
https://tenplay.com.au/news/national/2016/12/13/alzheimer-s-breakthrough
The same video should also appear here:
http://www.msn.com/en-au/sport/watch/alzheimers-breakthrough-for-aussie-patients/vp-AAluquB
I cannot see it because of location restriction. Video should be about Anavex but maybe it's different from the one we saw already.
It failed 13 times.
I already feel sorry for all those people who apply for trial access only to be turned away with a 'Sorry, no more seats available'.
Merry Christmas to you too Jimmy.
I mailed IR about this and this is what I got back:
I've been spreading the word on social media all day. I hope it helped :)
Small-Cap Biotech Stocks on the Rise in 2017
http://investorplace.com/2016/12/3-small-cap-biotech-stocks-for-2017-avxl-onvo-amrn/2/#.WFGF9X2m03E
I would rather tend to believe Anavex is the one with no interest in low balling offers from BP.
https://www.facebook.com/TheProjectTV/videos/10154154448498441/?pnref=story
Indeed. He is not to be trusted. Cramer said he was glad he had 'done his homework on AVXL'. A few days later the share price collapsed 80% from its all time high.
Even worse, they love shorting AVXL.
Simply astonishing! I urge investors living in the U.S.A. to share the video link and Falconer's splendid Anavex summary with Paul Ryan, who I believe will be in charge of Healthcare reform.
https://paulryan.house.gov/contact/email.htm
Hehe, yes I remember you re-invested part of your huge Apple gains to buy 400K shares AVXL pre-split and post-split. Congratulations, you'll be fine and so will be all the other longs. We keep the faith.
You mean this Jim Cramer?
Anavex's CEO Christopher Missling on Q4 2016 Results - Earnings Call (Transcript)
http://seekingalpha.com/article/4030260-anavexs-avxl-ceo-christopher-missling-q4-2016-results-earnings-call-transcript
I hope not or I will be forced to buy more shares AGAIN :)